releases: https://stefanik.house.gov/media-center/press-releases/stefanik-cosponsors-accelerating-access-critical-therapies-als-act
Data license: MIT · Data source: dwillis/congress-press
This data as json
| url | title | date | year | month | party | chamber | state | member_name | bioguide_id | domain | scraper | source | date_source | text | has_text | collected_at | updated_at |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| https://stefanik.house.gov/media-center/press-releases/stefanik-cosponsors-accelerating-access-critical-therapies-als-act | Stefanik Cosponsors Accelerating Access to Critical Therapies for ALS Act | 2020-11-24 | 2020 | 2020-11 | Republican | Senate | NY | Elise Stefanik | S001196 | stefanik.house.gov | legacy | Washington, D.C. Congresswoman Elise Stefanik is now a cosponsor of the Accelerating Access to Critical Therapies for ALS Act, bipartisan legislation that supports funding for research and treatments for ALS. This legislation retains a grant program that funds access to investigational ALS treatments and builds on the FDA's role in approving treatments and accelerating a path to better treatments and a cure. It also creates a new grant program at FDA, called the Rare Neurodegenerative Disease Grants program. Congresswoman Stefanik also sent a letter requesting support for the ALS Research Program and ALS Registry within the Department of Defense during this year's appropriations process. ALS is a disease that unfortunately effects many families in the North Country and throughout the United States, said Congresswoman Stefanik. This important bill supports investigational ALS treatments and initiates more collaboration between public private partners to allow federal agencies, patients, families, clinicians, and drug manufacturers to create a more successful path for drug discovery. It is crucial that we continue to fund research to find treatments and a cure for this devastating disease, and I look forward to furthering this effort along with my House colleagues. | 1 | 2026-03-30T12:14:52Z | 2026-03-30T12:14:52Z |